- Home
- Articles
- philippines
- therapeutic candidate
Refine by
Therapeutic Candidate Articles & Analysis
11 articles found
While the dangers of primary smoking are well-known, nearly half of the U.S. population remains at risk from the silent threat of secondhand smoke (SHS). Chronic exposure to SHS triggers a cascade of inflammation and vascular damage that can lead to irreversible conditions like COPD and emphysema. A recent study from Sturgis et al. (2025) has demonstrated a promising new therapeutic candidate: ...
Cancer treatment has witnessed transformative advancements over the past few decades, notably with the emergence of CAR-T (Chimeric Antigen Receptor T-cell) therapy. This revolutionary therapy harnesses the body's immune system by genetically engineering T-cells to target and destroy cancer cells. Among the pioneering companies at the forefront of this innovation is Alfa Cytology, renowned for ...
In recent years, the field of antibody drug design has become increasingly significant in the realm of therapeutic development, driven by the need for more effective and targeted treatments for various diseases, including cancer, autoimmune disorders, and infectious diseases. Antibodies, which are proteins produced by the immune system, have the ability to specifically recognize and bind to ...
Single-domain antibodies, also known as nanobodies or VHH antibodies, are a unique class of antibody fragments derived from the immune systems of camelids, such as llamas and alpacas. These small yet robust molecules present significant advantages in various applications, from therapeutics to diagnostics. This article explores the process of single-domain antibody production, its benefits, and ...
Breast cancer remains one of the most prevalent malignancies affecting women worldwide, necessitating innovative approaches for effective treatment and research. Among the most promising strategies in this endeavor are the use of tumor models for breast cancer and the development of customized antibody-drug conjugates (ADCs). These advancements not only enhance our understanding of the disease ...
The Latest Technological Advances in Antibody Discovery1. Single B Cell Isolation and SequencingThe isolation and sequencing of single B cells can help us gain a deeper understanding of the diversity and specificity of B cells. Through this method, we can clarify the relationship between the sequence and the cell, thus discovering antibodies with special properties. These antibodies may have high ...
I’m Anne Carpenter, a member of Recursion’s Scientific Advisory Board since 2014, a few months after the company was launched. I read Chris’ blog post reflecting on Recursion’s early days and thought I could tell my side of the story: watching Recursion get off the ground. I feel a bit sheepish as I recall grilling Recursion co-founders Chris Gibson and Blake ...
Study to be conducted at two leading research institutions in the U.K. Results will inform protocol design of Phase 1/2 clinical trial of Company's lead HSV-2 therapeutic vaccine candidate WOBURN, Mass. and OXFORD, England, Aug. 15, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced the ...
Insilico Medicine announced the nomination of a novel preclinical therapeutic candidate for treating COVID-19, designed using the generative chemistry AI platform Chemistry42. The new drug candidate is a 3CL protease inhibitor unique from existing drugs in its class because it can be rapidly produced. While this nomination is a potentially important development for the ongoing COVID-19 pandemic ...
Abstract The oncogene Ras and the tumor suppressor gene p53 are frequently co-mutated in human cancer and mutations in Ras and p53 can cooperate to generate a more malignant cell state. To discover novel druggable targets for cancers carrying co-mutations in Ras and p53, we performed arrayed, kinome focused siRNA and oncology drug phenotypic screening utilizing a set of syngeneic Ras mutant ...
A key hurdle to making adeno-associated virus (AAV) capsid mediated gene therapy broadly beneficial to all patients is overcoming pre-existing and therapy-induced immune responses to these vectors. Recent advances in high-throughput DNA synthesis, multiplexing and sequencing technologies have accelerated engineering of improved capsid properties such as production yield, packaging efficiency, ...